Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicohort study of atezolizumab in advanced solid tumors
2015-000269-30Phase 2Completed
- Sponsor
- Roche
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in Nonhematologic neoplasms, lung neoplasm, prostate cancer (PCa) and 1 more, sponsored by Roche. Primary endpoint: Non-progression rate at 18 weeks. Started Apr 2015; status: completed.
02
Drugs
atezolizumab
03
Conditions
Nonhematologic neoplasmslung neoplasmprostate cancer (PCa)pleural mesothelioma
Beyond the preview
Go deeper on 2015-000269-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000269-30.